Elixir Pharmaceuticals Establishes National Diabetes Advisory Board
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elixir Pharmaceuticals, Inc., announced today the formation of its U.S. Diabetes Advisory Board to provide independent scientific and clinical advice regarding the Company's product candidates in phase III development, Glinsuna™ (mitiglinide) and Metgluna™ (mitiglinide plus metformin), for the treatment of type 2 diabetes, as well as to provide input on other Elixir product candidates in development to treat metabolic diseases. James R. Gavin III, M.D., Ph.D., Clinical Professor of Medicine at Emory University and past president of the American Diabetes Association (ADA), has been named chair of the Elixir Diabetes Advisory Board. Members of the advisory board also include: Lawrence Blonde, M.D., Rhoda H. Cobin, M.D., John E. Gerich, M.D., Paul S. Jellinger, M.D., John L. Leahy, M.D. and Janet B. McGill, M.D.